| Literature DB >> 35764996 |
Yao Chen1, Xue Ke Zhao1, Rui Hua Xu1, Xin Song1, Miao Miao Yang1, Fu You Zhou2, Ling Ling Lei1, Zong Min Fan1, Xue Na Han1, She Gan Gao3, Xian Zeng Wang4, Zhi Cai Liu5, Ai Li Li5, Wen Jun Gao4, Jing Feng Hu1, Li Guo Zhang6, Jin Chang Wei7, Fu Lin Jiao7, Kan Zhong1, Wei Peng Wang8, Liu Yu Li1, Jia Jia Ji1, Xue Min Li8, Li Dong Wang9.
Abstract
BACKGROUND: This study compared the survival outcomes of different surgical approaches to determine the optimal approach for gastric cardia adenocarcinoma (GCA) and aimed to standardize the surgical treatment guidelines for GCA.Entities:
Keywords: Clinicopathology; Gastric cardia adenocarcinoma (GCA); Surgical approach; Survival
Mesh:
Year: 2022 PMID: 35764996 PMCID: PMC9238161 DOI: 10.1186/s12957-022-02680-5
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 3.253
The distribution of clinicopathological characteristics in 7103 GCA patients treated with different surgical approaches, n (%)
| Characteristics | No. of patients examined | Transthoracic ( | Thoracoabdominal ( | Transabdominal ( | ||||
|---|---|---|---|---|---|---|---|---|
| Sex | 0.24 | |||||||
| Male | 5600 | 4439 | (79) | 762 | (81) | 399 | (79) | |
| Female | 1503 | 1218 | (21) | 180 | (19) | 105 | (21) | |
| Age (years) | < 0.001* | |||||||
| < 40 | 64 | 44 | (1) | 15 | (2) | 5 | (1) | |
| 40–49 | 550 | 430 | (7) | 92 | (10) | 28 | (5) | |
| 50–59 | 2061 | 1692 | (30) | 258 | (27) | 111 | (22) | |
| 60–69 | 3145 | 2487 | (44) | 408 | (43) | 250 | (50) | |
| 70–79 | 1224 | 966 | (17) | 161 | (17) | 97 | (19) | |
| ≥ 80 | 59 | 38 | (1) | 8 | (1) | 13 | (3) | |
| Tumor stage | < 0.001† | |||||||
| 0 | 30 | 24 | (1) | 4 | (1) | 2 | (1) | |
| I | 328 | 250 | (4) | 38 | (4) | 40 | (8) | |
| II | 2991 | 2448 | (43) | 397 | (42) | 146 | (29) | |
| III | 3541 | 2813 | (50) | 454 | (48) | 274 | (54) | |
| IV | 213 | 122 | (2) | 49 | (5) | 42 | (8) | |
| N stage | 0.06 | |||||||
| N0 | 2737 | 2218 | (39) | 344 | (36) | 175 | (35) | |
| N1 | 4366 | 3439 | (61) | 598 | (64) | 329 | (65) | |
*Significant difference between the transthoracic and thoracoabdominal groups in the < 40 subgroup; significant difference between the thoracoabdominal and transabdominal groups in the 40 subgroups; significant difference between the transthoracic and transabdominal groups in the 50 subgroups and 60 subgroups; no significant difference among all three groups in the 70 subgroups; significant difference between the transabdominal and transthoracic and between the transabdominal and thoracoabdominal groups in the 80 subgroups
†No significant difference among all three groups among patients with stages 0 and 3 disease; significant difference between the transabdominal and transthoracic and between the transabdominal and thoracoabdominal groups among patients with stages 1 and 2 disease; significant difference between the transthoracic and thoracoabdominal and between the transthoracic and transabdominal groups among patients with stage 4 disease
Fig. 1Kaplan–Meier curves comparing different surgical approaches in 7103 GCA patients
Univariate analysis of the effects of clinicopathological characteristics on survival in 7103 GCA patients treated with different surgical approaches
| Characteristics | Median survival (95% | ||||
|---|---|---|---|---|---|
| Sex | |||||
| Male | 5.66 (5.37–5.94) | 4.66 (4.27–5.05) | 3.84 (3.15–4.53) | < 0.001* | < 0.001 |
| Female | 5.69 (5.08–6.29) | 5.73 (3.53–7.94) | 4.79 (3.60–5.98) | 0.32 | |
| Age (years) | |||||
| < 40 | 5.02 (1.93–8.12) | 3.29 (0.34–6.24) | Not reached | 0.34 | < 0.001 |
| 40–49 | 7.27 (5.23–9.31) | 7.27 (5.33–9.22) | 3.55 (1.98–5.12) | 0.10 | |
| 50–59 | 7.04 (6.34–7.74) | 4.95 (4.19–5.71) | 6.268 (4.22–8.32) | 0.02 | |
| 60–69 | 5.68 (5.31–6.04) | 4.73 (4.05–5.40) | 4.088 (3.33–4.84) | 0.002† | |
| 70–79 | 4.00 (3.65–4.36) | 3.50 (2.19–4.82) | 2.70 (1.72–3.68) | 0.005‡ | |
| ≥ 80 | 3.51 (2.84–4.18) | 3.55 (1.49–5.61) | 1.22 (0.56–1.88) | 0.16 | |
| Tumor stage | |||||
| 0/I | 13.09 (8.90–17.27) | 9.39 (4.49–14.29) | Not reached | 0.60 | < 0.001 |
| II | 7.70 (7.08–8.33) | 7.02 (5.26–8.78) | 6.95 (2.61–11.28) | 0.41 | |
| III | 4.23 (4.02–4.45) | 3.79 (3.31–4.27) | 3.16 (2.58–3.73) | < 0.001 | |
| IV | 4.99 (3.60–6.38) | 3.09 (1.51–4.68) | 3.01 (1.53–4.50) | 0.03 | |
| N stage | |||||
| N0 | 8.99 (8.23–9.75) | 8.51 (6.38–10.64) | 6.95 (2.67–11.22) | 0.31 | < 0.001 |
| N1 | 4.46 (4.26–4.67) | 3.93 (3.55–4.31) | 3.16 (2.66–3.67) | < 0.001 | |
*Transthoracic vs. thoracoabdominal, P < 0.001; transthoracic vs. transabdominal, P < 0.001; thoracoabdominal vs. transabdominal, P = 0.08
†Transthoracic vs. thoracoabdominal, P = 0.12; transthoracic vs. transabdominal, P = 0.001; thoracoabdominal vs. transabdominal, P = 0.08
‡Transthoracic vs. thoracoabdominal, P = 0.20; transthoracic vs. transabdominal, P = 0.001; thoracoabdominal vs. transabdominal, P = 0.14
Univariable analysis and Cox multivariate regression analysis for 7103 GCA patients
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| Sex | ||||
| Female vs. male | 0.90 (0.84–0.97) | 0.004 | 0.88 (0.82–0.95) | < 0.001 |
| Age (years) | ||||
| 40–49 vs. < 40 | 0.79 (0.57–1.08) | 0.14 | 0.89 (0.65–1.22) | 0.46 |
| 50–59 vs. < 40 | 0.93 (0.69–1.26) | 0.63 | 1.05 (0.77–1.42) | 0.76 |
| 60–69 vs. < 40 | 1.15 (0.85–1.56) | 0.36 | 1.31 (0.97–1.77) | 0.08 |
| 70–79 vs. < 40 | 1.64 (1.20–2.22) | 0.002 | 1.87 (1.37–2.53) | < 0.001 |
| ≥ 80 vs. < 40 | 2.49 (1.65–3.75) | < 0.001 | 2.59 (1.72–3.91) | < 0.001 |
| Tumor stage | ||||
| II vs. 0/I | 1.54 (1.27–1.85) | < 0.001 | 1.56 (1.29–1.88) | < 0.001 |
| III vs. 0/I | 2.54 (2.11–3.07) | < 0.001 | 2.60 (2.16–3.13) | < 0.001 |
| IV vs. 0/I | 2.37 (1.87–3.01) | < 0.001 | 2.36 (1.86–3.00) | < 0.001 |
| Surgical approach | ||||
| Thoracoabdominal vs. transthoracic | 1.15 (1.06–1.25) | 0.001 | 1.16 (1.07–1.26) | < 0.001 |
| Transabdominal vs. transthoracic | 1.38 (1.21–1.56) | < 0.001 | 1.31 (1.16–1.49) | < 0.001 |
95% CI 95% confidence interval, HR hazard ratio